Delving into the Latest Updates on Armillariella Oral Solution with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Digestive System DisordersHemic and Lymphatic Diseases

Active Indication

CholangitisCholecystitisGastritis+ [2]

Inactive Indication-

Originator Organization

Sichuan Xiantong Pharmaceutical Co., Ltd.

Active Organization

Hefei Chengzhi Biological Pharmaceutical Co., Ltd

Sichuan Xiantong Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

China (01 Jan 1995)

Regulation-

Login to view timeline

This is a Phase 1, double-blind, randomized, placebo-controlled, single-dose and multiple-dose study of CRN01941 in up to 119 healthy male and female subjects. This single-center study will be conducted in 3 parts: a single-ascending dose phase (up to 8 cohorts, 8 subjects/cohort), a multiple-ascending dose phase (up to 5 cohorts, 9 subjects/cohort), and single dose phase in elderly subjects (1 cohort, 10 subjects).

Start Date29 Apr 2019

Sponsor / Collaborator

Crinetics Pharmaceuticals, Inc.

NCT02265302

/ CompletedPhase 1

A Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, Biological Effects and Preliminary Pharmacokinetics of Increasing Single Oral Doses of BIIL 284 BS (Dose Range: 0.025 mg - 75 mg PSE Solution, 25 mg, 75 mg, 250 mg and 750 mg WIF Tablets) in Healthy Male Volunteers as Well as Food Effects at 75 mg (WIF Tablet)

Study to obtain information about the safety and tolerability of BIIL 248 BS, to find the pharmacologically active dose range for the two formulations PSE 1% and WIF tablets by determination of the surrogate marker CD11b (= Mac-1) and to obtain preliminary pharmacokinetic data as well as first information on food effects after administration of the 75 mg WIF tablet in healthy male volunteers

Start Date01 Jun 1998

Sponsor / Collaborator

Boehringer Ingelheim GmbH

100 Clinical Results associated with Armillariella Oral Solution

Login to view more data

100 Translational Medicine associated with Armillariella Oral Solution

Login to view more data

100 Patents (Medical) associated with Armillariella Oral Solution

Login to view more data

100 Deals associated with Armillariella Oral Solution

Login to view more data

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Cholangitis	China	Hefei Chengzhi Biological Pharmaceutical Co., Ltd	01 Jan 2002
Cholecystitis	China	Hefei Chengzhi Biological Pharmaceutical Co., Ltd	01 Jan 2002
Gastritis	China	Hefei Chengzhi Biological Pharmaceutical Co., Ltd	01 Jan 2002
Hepatitis	China	Hefei Chengzhi Biological Pharmaceutical Co., Ltd	01 Jan 2002
Leukopenia	China	Hefei Chengzhi Biological Pharmaceutical Co., Ltd	01 Jan 2002